0001314102 2025-10-15 2025-10-15 0001314102 1 2025-10-15 2025-10-15 0001314102 2 2025-10-15 2025-10-15 0001314102 3 2025-10-15 2025-10-15 0001314102 1 2025-10-15 2025-10-15 0001314102 2 2025-10-15 2025-10-15 iso4217:USD pure shares S-3 424B5 EX-FILING FEES 333-290867 0001314102 EyePoint Pharmaceuticals, Inc. N/A false true false S-3 EyePoint Pharmaceuticals, Inc. false Equity Common Stock, $0.001 par value per share true 12875000 12.00 154500000.00 0.0001381 21336.45 false Equity Common Stock, par value $0.001 per share, issuable upon exercise of Pre-Funded Warrants true 1500000 12.00 18000000.00 0.0001381 2485.80 false Equity Pre-Funded Warrants to purchase Common Stock true 1500000 0.00 0.0001381 0.00 172500000.00 23822.25 0.00 23822.25 0.00 In accordance with Rules 456(b) and 457(r) under the Securities Act, the Registrant initially deferred payment of all of the registration fee for Registration Statement on Form S-3 (File No. 333-290867), which was filed with the Securities and Exchange Commission (the "SEC") on August 14, 2025. Per Rule 457(i) under the Securities Act, the proposed maximum offering price per share of Common Stock issuable upon exercise of each Pre-Funded Warrant represents the sum of the $11.999 public offering price of the Pre-Funded Warrants and the $0.001 exercise price of each Pre-Funded Warrant. In accordance with Rules 456(b) and 457(r) under the Securities Act, the Registrant initially deferred payment of all of the registration fee for the Registration Statement on Form S-3 (File No. 333-290867), which was filed with the SEC on August 14, 2025. The entire fee is allocated to the Common Stock issuable upon exercise of Pre-Funded Warrants. true EyePoint Pharmaceuticals, Inc. S-3 333-281391 2024-08-08 23822.25 Equity Common Stock, par value $0.0001 per share 227354232.00 true EyePoint Pharmaceuticals, Inc. S-3 333-281391 2024-08-08 23822.25 Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $227,354,232 of unsold securities (the "Unsold Securities") previously registered pursuant to the registrant's Registration Statement on Form S-3 (File No. 333-281391) filed with the Securities and Exchange Commission on August 8, 2024 and declared effective on August 16, 2024 (the "Prior Registration Statement"). The Prior Registration Statement registered securities for primary offerings in accordance with Rule 415(a)(1)(x) with a proposed maximum aggregate offering price of $400,000,000. The registrant sold an aggregate of $172,645,768 of such securities under the Prior Registration Statement, leaving the balance of $227,354,232 of Unsold Securities, in respect of which the registrant paid an aggregate registration fee of $23,822.25 (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement). Pursuant to Rule 415(a)(6), the filing fee of $23,822.25 associated with the offering of the Unsold Securities is hereby applied to offset the filing fees due in connection with the securities registered hereunder of $23,822.25. Pursuant to Rule 457(p) under the Securities Act, the offering of the Unsold Securities under the Prior Registration Statement has terminated.